OncoArendi Therapeutics SA Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • OncoArendi Therapeutics SA's estimated annual revenue is currently $13.8M per year.(i)
  • OncoArendi Therapeutics SA's estimated revenue per employee is $155,000

Employee Data

  • OncoArendi Therapeutics SA has 89 Employees.(i)
  • OncoArendi Therapeutics SA grew their employee count by 7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$15.3M99-49%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.5M29-6%N/AN/A
#10
$9.6M62-7%N/AN/A
Add Company

OncoArendi Therapeutics SA (WSE:OAT) is a Polish innovative biotechnology company specializing in research, development and commercialization of innovative small molecule drugs for treatment of respiratory diseases and cancer. Researchers at OncoArendi study the role of chitinases and chitinase-like-proteins that provide multiple opportunities for therapeutic interventions. OncoArendi currently has a platform of distinct small molecule programs targeting this classes of proteins, which may have potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. OncoArendi is also focusing on the development of small molecule immune-modulators targeting a key enzyme involved in amino acid metabolism that allows tumor cells to hamper anti-tumor immunity and to avoid immune surveillance. OncoArendi Therapeutics' business model is based on the discovery and development of first-in class or best-in-class small molecules, and then outlicensing its assets to larger pharmaceutical and biotechnology companies. The company has been listed on the WSE main market) since April 2018. More information at www.oncoarendi.com.

keywords:N/A

N/A

Total Funding

89

Number of Employees

$13.8M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

OncoArendi Therapeutics SA News

2022-04-17 - Tech Transfer Roundup: Lysogene Elects Option On Gene ...

Cellevolve, Seattle Children's partner on cell therapies for CNS ... OncoArendi Therapeutics SA signed an option-to-license agreement on 11...

2022-03-22 - OncoArendi Therapeutics Reports Continued Strategic and ...

WARSAW, Poland, March 25, 2022 /PRNewswire/ -- OncoArendi Therapeutics S.A. ("OncoArendi") (WSE: OAT), a clinical stage biopharmaceutical...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.9M8944%N/A
#2
$9M8914%N/A
#3
$18.2M907%N/A
#4
$11.7M90-17%N/A
#5
$6.5M90-6%N/A